

OPEN

Steady-state activation of the high-affinity isoform of the $\alpha 4\beta 2\delta$ GABA_A receptor

Spencer R. Pierce¹, Thomas C. Senneff¹, Allison L. Germann¹ & Gustav Akk^{1,2*}

Activation of GABA_A receptors consisting of $\alpha 4$, $\beta 2$ (or $\beta 3$), and δ subunits is a major contributor to tonic inhibition in several brain regions. The goal of this study was to analyze the function of the $\alpha 4\beta 2\delta$ receptor in the presence of GABA and other endogenous and clinical activators and modulators under steady-state conditions. We show that the receptor has a high constitutive open probability (~0.1), but is only weakly activated by GABA that has a maximal peak open probability ($P_{\text{Open,peak}}$) of 0.4, taurine (maximal $P_{\text{Open,peak}} = 0.4$), or the endogenous steroid allopregnanolone (maximal $P_{\text{Open,peak}} = 0.2$). The intravenous anesthetic propofol is a full agonist (maximal $P_{\text{Open,peak}} = 0.99$). Analysis of currents using a cyclic three-state Resting-Active-Desensitized model indicates that the maximal steady-state open probability of the $\alpha 4\beta 2\delta$ receptor is ~0.45. Steady-state open probability in the presence of combinations of GABA, taurine, propofol, allopregnanolone and/or the inhibitory steroid pregnenolone sulfate closely matched predicted open probability calculated assuming energetic additivity. The results suggest that the receptor is active in the presence of physiological concentrations of GABA and taurine, but, surprisingly, that receptor activity is only weakly potentiated by propofol.

Activation of the Cl⁻ permeable GABA_A receptor contributes to cellular inhibition. The two principal types of the GABA_A receptor in the central nervous system are the synaptic receptor that is activated phasically by pre-synaptically released GABA, and the extrasynaptic receptor that is activated tonically by ambient GABA. Native GABA_A receptors in the brain are additionally exposed to a number of endogenous GABAergic agents including taurine (2-aminoethanesulfonic acid) and potentiating and inhibitory neurosteroids, that can amplify or inhibit the response to the transmitter. Furthermore, both the synaptic and extrasynaptic GABA_A receptors are activated and modulated by clinically used GABAergic sedatives and anesthetics such as propofol and etomidate^{1,2}. The two types of receptors differ in their subunit composition; synaptic receptors comprise $\alpha 1-3$, $\beta 2-3$, and $\gamma 2$ subunits, whereas extrasynaptic receptors typically consist of $\alpha 4$, $\beta 2-3$, and δ subunits.

With few exceptions^{3,4}, previous functional studies of the $\alpha 4\beta 2\delta$ receptor have concentrated on recording peak current responses, i.e., maximal responses to short-duration applications of one or more agonists. It may be argued that this approach does not accurately reflect native conditions, which can be characterized as essentially infinite-duration exposure to a low concentration of GABA with slowly developing changes in the concentrations of other endogenous agonists and modulators and, if so administered, GABAergic clinical agents. This discrepancy between typical experimental and the presumed *in vivo* conditions makes prediction of normal behavior of the native extrasynaptic receptor and properties of tonic inhibition challenging.

We recently described derivation and properties of a three-state Resting-Active-Desensitized (“RAD”) model⁵. The model (Fig. 1), which was initially employed to quantitatively describe steady-state activity in the synaptic-type $\alpha 1\beta 2\gamma 2L$ GABA_A receptor activated by a single agonist, could also be used to accurately predict steady-state activity in the presence of multiple potentiating and inhibitory agents. Here, we have employed the RAD model to investigate the properties of the human $\alpha 4\beta 2\delta$ expressed in *Xenopus* oocytes. A major goal of the study was to elucidate steady-state activity in the presence of multiple endogenous and clinical activating (GABA, taurine, propofol, allopregnanolone) and inhibitory (pregnenolone sulfate) agents to predict the behavior of the extrasynaptic GABA_A receptor under conditions mimicking the native pharmacological environment.

We show that the receptor has a constitutive open probability of ~0.1 and a steady-state open probability ($P_{\text{Open,S.S.}}$) near 0.3 in the presence of saturating GABA. The receptor is potently activated by the transmitter

¹Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, 63110, USA. ²The Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, 63110, USA. *email: akk@morpheus.wustl.edu




Figure 1. The Resting-Active-Desensitized (RAD) model. The model is shown for agonist X (e.g., GABA) that has two binding sites on the receptor. The receptor can occupy a resting (R), active (A), or desensitized (D) state. The resting and desensitized states are non-conducting, and the active state is conducting (also called “open”). The active and desensitized states have higher affinity to the agonist than the resting state. The parameter L (=R/A) describes the equilibrium between the resting and active states, and the parameter Q (=A/D) describes the equilibrium between the active and desensitized states. K_X is the equilibrium dissociation constant for agonist X of the resting receptor. $K_X c_X$ is the equilibrium dissociation constant for agonist X of the active receptor, and $K_X c_X d_X$ is the equilibrium dissociation constant for X of the desensitized receptor. The inhibitory steroid PS has high affinity to the desensitized state and low affinity to the resting and active states. For the agonists studied, the ratio of affinities for the active and desensitized states (d) is close to 1 (see text for additional discussion). The behavior of the receptor in the RAD model is described by Eqs (1–3).

GABA, the orthosteric agonist taurine, and the allosteric agonists propofol and allopregnanolone (3 α 5 α P). An agreement between the $P_{Open,S.S.}$ calculated using equations derived from the RAD model and the $P_{Open,S.S.}$ observed experimentally upon coapplication of combinations of GABA, taurine, propofol, 3 α 5 α P, and the inhibitory steroid pregnenolone sulfate (PS) indicates that the drugs act energetically additively.

Results

Activation and desensitization by the orthosteric agonists GABA and taurine. The oocytes expressing $\alpha 4\beta 2\delta$ GABA_A receptors respond to application of GABA with inward current. Concentration-response measurements carried out in the presence of 0.3–1000 nM GABA yielded an EC_{50} of 20 ± 10 nM and a Hill coefficient of 0.80 ± 0.09 (mean \pm S.D.; $n = 6$ cells). Sample current traces in the presence of GABA are shown in Fig. 2A.

To convert the raw current amplitudes to units of open probability (P_{Open}), we compared the response to saturating GABA (0.3 μ M) to the response to 300 μ M picrotoxin (PTX) and the response to 10 μ M GABA + 50 μ M propofol. The details of this approach have been reported previously^{6,7}. Blockade of activity from constitutively active receptors by PTX is expected to lead to zero GABAergic activity (P_{Open} approaching 0), and receptor activation by the combination of saturating GABA and a high concentration of propofol is expected to generate a maximal possible peak response with a P_{Open} indistinguishable from 1. Comparison of the holding current and peak responses to PTX, GABA, and GABA + propofol, yielded an estimate of 0.13 ± 0.09 ($n = 24$ cells) for constitutive open probability ($P_{Open,const}$), and an estimate of 0.35 ± 0.09 ($n = 22$ cells) for open probability in the presence of 0.3 μ M GABA. Sample current responses to PTX, GABA, and GABA + propofol are given in Fig. 2B.

The activation parameters for peak responses were determined by fitting the P_{Open} data to Eq. (1)^{8,9}:

$$P_{Open,Peak} = \frac{1}{1 + L \left[\frac{1 + [X] / K_X}{1 + [X] / (K_X c_X)} \right]^{N_X}} \quad (1)$$

where $[X]$ is the concentration of agonist X (GABA in this experiment), K_X is the equilibrium dissociation constant for agonist X of the resting receptor, c_X is the ratio of the equilibrium dissociation constant for X of the open receptor to K_X , and N_X is the number of agonist binding sites. L expresses the level of background activity, and can be calculated from constitutive activity as: $(1 - P_{Open,const}) / P_{Open,const}$.

Curve-fitting of pooled data from 6 cells to Eq. (1) yielded a K_{GABA} of 15.7 ± 2.3 nM (best-fit parameter \pm S.E. of the fit) and a c_{GABA} of 0.45 ± 0.01 . The number of GABA binding sites was held at two¹⁰. The concentration-response relationship for peak currents is given in Fig. 2C.

The data indicate that GABA is a weak agonist of the $\alpha 4\beta 2\delta$ receptor. The binding of two GABA molecules contributes only 0.94 kcal/mol ($N_{GABA} RT \times \ln(c_{GABA})$) towards stabilization of the open state. For comparison, in the synaptic-type $\alpha 1\beta 2\gamma 2L$ receptor, the binding of two GABA molecules contributes 6.4–7.5 kcal/mol of




Figure 2. Activation of the $\alpha 4\beta 2\delta$ receptor by GABA. **(A)** Sample current traces showing activation by 0.3 nM (left), 3 nM (middle), or 30 nM (right) GABA. The dashed lines show the estimated steady-state current levels. **(B)** Sample current traces showing inhibition of constitutively active receptors by 300 μ M picrotoxin (PTX; $P_{\text{Open}} = 0$), or activation of resting receptors by 0.3 μ M GABA (maximal $P_{\text{Open,GABA}} = 0.4$), or activation of resting receptors by 10 μ M GABA + 50 μ M propofol ($P_{\text{Open}} = 1$). **(C)** GABA concentration-response relationship. The data points show mean \pm S.D. from at least five cells per concentration. The curve for peak currents was fitted using Eq. (1). The best-fit parameters are: $K_{\text{GABA}} = 15.7 \pm 2.3$ nM, $c_{\text{GABA}} = 0.45 \pm 0.01$. The number of GABA binding sites was constrained to 2. The curve for steady-state currents was fitted using Eq. (2) with the K_{GABA} and c_{GABA} values constrained to those determined in fitting the peak currents. The best-fit value for Q was 0.78 ± 0.08 . Curve-fitting was carried out using Origin v. 7.5 (OriginLab, Northampton, MA) on pooled data.

stabilization energy^{11,12}. Thus, despite the relatively high constitutive open probability (i.e., low intrinsic energy barrier towards channel opening), the theoretical peak maximal open probability of the $\alpha 4\beta 2\delta$ receptor in the presence of GABA, calculated as $1/(1 + Lc_{\text{GABA}}^{N_{\text{GABA}}})$, is only 0.44. This is in agreement with previous estimates in single-channel and macroscopic studies demonstrating that GABA is a partial agonist of the $\alpha 4\beta 2\delta$ receptor^{13–17}.

To analyze the desensitization properties of the $\alpha 4\beta 2\delta$ receptor, we fitted the concentration-response relationship for steady-state currents to Eq. (2)⁵:

$$P_{\text{Open,S.S.}} = \frac{1}{1 + \frac{1}{Q} + L \left[\frac{1 + [X]/K_X}{1 + [X]/(K_X c_X)} \right]^{N_X}} \quad (2)$$

The parameter Q (=A/D) reflects the equilibrium between the active and desensitized states (Fig. 1). The other terms are as described for Eq. (1). Curve fitting of steady-state responses, using K_{GABA} and c_{GABA} constrained to the values determined for peak currents in the same set of cells, yielded an estimate of 0.78 ± 0.08 for Q. Thus, under steady-state conditions, the ratio of open/active vs. desensitized receptors is $\sim 4:5$.

Taurine, an endogenous sulfonic acid and a structural analog of GABA, can activate the GABA_A receptor^{18–21}. Its effects are likely mediated through interactions with the transmitter binding sites, as suggested by molecular modeling²² and the finding that the $\beta 2$ (Y205S) mutation in the transmitter binding site that abolishes receptor activation by GABA¹⁰ also eliminates activation of the $\alpha 1\beta 2\gamma 2L$ and $\alpha 4\beta 2\delta$ receptors by taurine (<0.2% of the response to GABA + propofol; data not shown).

Taurine concentration-response measurements on oocytes expressing the $\alpha 4\beta 2\delta$ GABA_A receptor yielded an EC_{50} of 9.8 ± 4.8 μ M and a Hill coefficient of 0.70 ± 0.08 ($n = 6$ cells) for peak currents. Fitting the concentration-response data to Eq. (1) gave the estimates of K_{taurine} of 10.0 ± 2.1 μ M and a c_{taurine} of 0.47 ± 0.02 . Thus, taurine and GABA have similar gating efficacies (i.e., $c_{\text{taurine}} \approx c_{\text{GABA}}$) on the $\alpha 4\beta 2\delta$ receptor and maximal peak open probabilities (0.44 and 0.42, respectively). In recordings in the presence of long (190–410 s) applications of 1 mM taurine, the steady-state open probability was 0.23 ± 0.04 ($n = 5$ cells), yielding a calculated value of 0.52 for Q.

Activation and desensitization by the allosteric agonists propofol and 3 α 5 α P. The propofol concentration-response relationship was obtained by exposing oocytes expressing the $\alpha 4\beta 2\delta$ receptor to 0.2–20 μ M propofol. Curve-fitting the peak response data with the Hill equation yielded an EC_{50} of 7.3 ± 2.0 μ M and a




Figure 3. Activation of the $\alpha 4\beta 2\delta$ receptor by propofol. (A) Sample current traces showing activation by $1\ \mu\text{M}$ (left) or $20\ \mu\text{M}$ (right) propofol. The dashed lines show the estimated steady-state current levels. (B) Propofol concentration-response relationship. The data points show mean \pm S.D. from at least five cells per concentration. The curve for peak currents was fitted using Eq. (1). The best-fit parameters are: $K_{\text{propofol}} = 55.1 \pm 6.6\ \mu\text{M}$, $c_{\text{propofol}} = 0.16 \pm 0.01$. The number of propofol binding sites was held at 4. The curve for steady-state currents was fitted using Eq. (2) with the K_{propofol} and c_{propofol} values constrained to those determined in fitting the peak currents. The best-fit value for Q was 1.29 ± 0.14 . Curve-fitting was carried out using Origin v. 7.5 (OriginLab, Northampton, MA) on pooled data.

Hill coefficient of 2.17 ± 0.65 ($n = 6$ cells). Fitting the pooled data to Eq. (1) gave a K_{propofol} of $55.1 \pm 6.6\ \mu\text{M}$ and a c_{propofol} of 0.16 ± 0.01 . The number of binding sites for propofol was constrained to 4. Thus, the binding of propofol to the $\alpha 4\beta 2\delta$ receptor contributes 4.3 kcal/mol towards stabilization of the open state. The predicted maximal peak P_{Open} in the presence of propofol is ~ 0.99 . Sample current responses and the concentration-response curves are given in Fig. 3.

Curve-fitting the peak response data recorded in the presence of $0.01\text{--}3\ \mu\text{M}$ $3\alpha 5\alpha\text{P}$ yielded an EC_{50} of $0.23 \pm 0.10\ \mu\text{M}$ and a Hill coefficient of 1.17 ± 0.30 ($n = 6$ cells). Analysis of the peak currents using Eq. (1) gave a $K_{3\alpha 5\alpha\text{P}}$ of $0.21 \pm 0.04\ \mu\text{M}$ and a $c_{3\alpha 5\alpha\text{P}}$ of 0.68 ± 0.01 with the number of binding sites for $3\alpha 5\alpha\text{P}$ held at 2. Sample current responses and the concentration-response relationships are shown in Fig. 4.

To determine receptor desensitization properties in the presence of propofol or $3\alpha 5\alpha\text{P}$, we analyzed the steady-state currents using Eq. (2). With the K and c values constrained to the values estimated by analyzing peak responses, we obtained the estimates for Q of 1.29 ± 0.14 in the presence of propofol, and 0.89 ± 0.33 in the presence of $3\alpha 5\alpha\text{P}$. A higher value of Q is associated with reduced desensitization, i.e., a higher steady-state to peak ratio.

We recently showed that propofol enhances steady-state activity elicited by saturating GABA in the $\alpha 1\beta 2\gamma 2\text{L}$ receptor²³. The effect, which is observed as an increase in the apparent value of Q , was attributed to propofol having a higher affinity to the open vs. desensitized state. To determine whether an analogous mechanism underlies the higher value of Q in the $\alpha 4\beta 2\delta$ receptor activated by propofol, we compared the potentiating effect of propofol on peak and steady-state currents elicited by saturating GABA. We reasoned that if propofol potentiates the responses by enhancing receptor open probability then the potentiating effect will be similar for peak and steady-state activity. On the other hand, if propofol additionally reduces receptor desensitization, then the potentiating effect of propofol on steady-state current should exceed that on the peak response. In five cells, coapplication of $1\ \mu\text{M}$ propofol enhanced the peak response to $0.3\ \mu\text{M}$ GABA to $151 \pm 12\%$ of control. Application of $1\ \mu\text{M}$ propofol on steady-state response elicited by $0.3\ \mu\text{M}$ GABA augmented the response to $145 \pm 14\%$ of control ($n = 5$ cells). We infer that within the limits of our experimental precision, propofol does not modify the equilibrium between active and desensitized states.

Modulation of steady-state current by PS. The endogenous steroid PS promotes desensitization of the synaptic-type $\alpha\beta\gamma$ GABA_A receptor^{5,24,25}. Here, we determined the effect of PS on the $\alpha 4\beta 2\delta$ receptor.

The receptors were activated by a prolonged application of $0.3\ \mu\text{M}$ GABA. Once steady-state response was reached, the flow was switched to GABA + PS. The concentration of PS ranged from 0.1 to $10\ \mu\text{M}$. Curve-fitting




Figure 4. Activation of the $\alpha 4\beta 2\delta$ receptor by $3\alpha 5\alpha P$. (A) Sample current traces showing activation by $0.1 \mu M$ (left) or $3 \mu M$ (right) $3\alpha 5\alpha P$. The dashed lines show the estimated steady-state current levels. (B) $3\alpha 5\alpha P$ concentration-response relationship. The data points show mean \pm S.D. from at least five cells per concentration. The curve for peak currents was fitted using Eq. (1). The best-fit parameters are: $K_{3\alpha 5\alpha P} = 0.21 \pm 0.04 \mu M$, $c_{3\alpha 5\alpha P} = 0.68 \pm 0.01$. The number of $3\alpha 5\alpha P$ binding sites was held at 2. The curve for steady-state currents was fitted using Eq. (2) with the $K_{3\alpha 5\alpha P}$ and $c_{3\alpha 5\alpha P}$ values constrained to those determined in fitting the peak currents. The best-fit value for Q was 0.89 ± 0.33 . Curve-fitting was carried out using Origin v. 7.5 (OriginLab, Northampton, MA) on pooled data.

of pooled data from 5–7 cells per concentration gave an IC_{50} of $1.4 \pm 0.3 \mu M$ and a high concentration asymptote of $50 \pm 4\%$ of control.

In the framework of the RAD model, PS inhibits receptor activity by binding with high affinity to the desensitized state and with low affinity to the resting and active states. For receptors activated by GABA, the open probability in the presence of PS is:

$$P_{Open,S.S.} = \frac{1}{1 + \frac{1}{Q} \left(\frac{1 + [PS]/(K_{PS}d_{PS})}{1 + [PS]/K_{PS}} \right) + L \left[\frac{1 + [GABA]/K_{GABA}}{1 + [GABA]/(K_{GABA}c_{GABA})} \right]^{N_{GABA}}} \quad (3)$$

where K_{PS} is the equilibrium dissociation constant of the resting and active receptors to PS, and d_{PS} is the ratio of the equilibrium dissociation constant of the desensitized receptor to K_{PS} . The number of sites for PS was assumed to be 1. Other terms are as described above for Eqs (1,2).

In this model, PS does not modify the intrinsic properties of the receptor (i.e., L or Q) or the parameters of receptor activation by GABA (i.e., K_{GABA} or c_{GABA}). Fitting the PS concentration-response data to Eq. (3) yielded a K_{PS} of $2.6 \pm 0.6 \mu M$, and a d_{PS} of 0.14 ± 0.02 . The K_{PS} and d_{PS} estimates are similar to the values previously determined for the $\alpha 1\beta 2\gamma 2L$ receptor ($1.9 \mu M$ and 0.11 , respectively)²³. Sample current traces, the concentration-response data, and the fitted curve are shown in Fig. 5.

Steady-state activation in the presence of combinations of GABA, taurine, propofol, $3\alpha 5\alpha P$ and/or PS. We previously showed for the $\alpha 1\beta 2\gamma 2L$ GABA_A receptor that steady-state activity in the presence of multiple active agents is determined by energetic additivity^{5,23}. To verify that the same mechanism determines steady-state activity of the $\alpha 4\beta 2\delta$ receptor, and to gain insight into receptor function in the presence of multiple endogenous and clinical activators and modulators, we measured steady-state responses in the presence of combinations of orthosteric (GABA, taurine) and allosteric activators (propofol, $3\alpha 5\alpha P$) and inhibitors (PS). The experimentally observed $P_{Open,S.S.}$ was compared with the predicted $P_{Open,S.S.}$. The latter can be calculated using Eq. (4):

$$P_{Open,S.S.} = \frac{1}{1 + \frac{1}{Q} \left(\frac{1 + [PS]/(K_{PS}d_{PS})}{1 + [PS]/K_{PS}} \right) + L \left[\frac{1 + [GABA]/K_{GABA} + [taurine]/K_{taurine}}{1 + [GABA]/(K_{GABA}c_{GABA}) + [taurine]/(K_{taurine}c_{taurine})} \right]^{N_{transmitter}} \Gamma_{propofol} \Gamma_{3\alpha 5\alpha P}} \quad (4)$$

where $\Gamma_{propofol}$ is:




Figure 5. Inhibition of the $\alpha 4\beta 2\delta$ receptor by pregnenolone sulfate. **(A)** Sample current traces showing the effects of $0.2\ \mu\text{M}$ (left) or $5\ \mu\text{M}$ (right) pregnenolone sulfate (PS) on steady-state current elicited by $0.3\ \mu\text{M}$ GABA. The rebound current following washout of GABA + $5\ \mu\text{M}$ PS likely results from faster washout of PS revealing activity of GABA-bound active receptors. **(B)** PS concentration-response relationship in the presence of $0.3\ \mu\text{M}$ GABA. The data points show mean \pm S.D. from at least five cells per concentration. The curve was fitted with Eq. (3), yielding a K_{PS} of $2.6 \pm 0.7\ \mu\text{M}$ and a c_{PS} of 0.14 ± 0.02 . The number of PS binding sites was held at 1. Curve-fitting was carried out using Origin v. 7.5 (OriginLab, Northampton, MA) on pooled data. The fitted values for K_{PS} and c_{PS} are given as best-fit parameter \pm standard error of the fit.

$$\Gamma_{[\text{propofol}]} = \left[\frac{1 + [\text{propofol}]/K_{\text{propofol}}}{1 + [\text{propofol}]/(K_{\text{propofol}}c_{\text{propofol}})} \right]^{N_{\text{propofol}}} \quad (5)$$

and $\Gamma_{3\alpha 5\alpha P}$ is:

$$\Gamma_{[3\alpha 5\alpha P]} = \left[\frac{1 + [3\alpha 5\alpha P]/K_{3\alpha 5\alpha P}}{1 + [3\alpha 5\alpha P]/(K_{3\alpha 5\alpha P}c_{3\alpha 5\alpha P})} \right]^{N_{3\alpha 5\alpha P}} \quad (6)$$

In practice, however, the predicted $P_{\text{Open,S.S.}}$ was calculated using Eq. (7):

$$P_{\text{Open,S.S.}} = \frac{1}{1 + \frac{1}{Q} \left(\frac{1 + [\text{PS}]/(K_{\text{PS}}d_{\text{PS}})}{1 + [\text{PS}]/K_{\text{PS}}} \right) + \Pi_{\text{Sum}}} \quad (7)$$

where Π_{Sum} is a measure of peak activation by the mixture of agonists and is related to the peak open probability as:

$$\Pi_{\text{Sum}} = \frac{1}{P_{\text{Open,peak}}} - 1 \quad (8)$$

Equations (7) and (8) express steady-state open probability as a dependent product of peak open probability, related to it through Q and the effect of PS (K_{PS} and d_{PS}) on steady-state current. This approach enabled us to compensate for cell-to-cell variability in the actions of agonist mixtures.

In total, 8 combinations of drugs and drug concentrations were tested. The concentration of GABA ranged from $10\ \text{nM}$ to $10\ \mu\text{M}$, taurine from 10 to $100\ \mu\text{M}$, propofol from 1 to $50\ \mu\text{M}$, $3\alpha 5\alpha P$ from 10 to $30\ \text{nM}$, and PS




Figure 6. Steady-state activation of the $\alpha 4\beta 2\delta$ receptor by combinations of orthosteric and allosteric agonists and the inhibitory steroid PS. The graph shows the observed and predicted P_{Open} of steady-state responses in the presence of 100 nM GABA + 10 μM taurine + 30 nM $3\alpha 5\alpha\text{P}$ + 0.1 μM PS (drug combination #1), 100 nM GABA + 10 μM taurine + 30 nM $3\alpha 5\alpha\text{P}$ + 0.1 μM PS + 1 μM propofol (#2), 10 nM GABA + 10 μM taurine + 10 nM $3\alpha 5\alpha\text{P}$ + 1 μM PS (#3), 300 nM GABA + 100 μM taurine + 30 nM $3\alpha 5\alpha\text{P}$ + 1 μM propofol (#4), 100 nM GABA + 10 μM taurine + 0.2 μM PS (#5), 10 μM GABA + 50 μM propofol (#6), 10 μM GABA + 50 μM propofol + 1 μM PS (#7), 10 μM GABA + 50 μM propofol + 0.1 μM PS (#8). The predicted $P_{\text{Open,S.S.}}$ were determined using Eq. (7). The open symbols show data from individual cells. The filled symbols show mean \pm S.D. Drug combinations #6–8 contained 10 μM GABA + 50 μM propofol that generates a peak P_{Open} indistinguishable from 1. Accordingly, the S.D. for predicted $P_{\text{Open,S.S.}}$ are not shown for these combinations. The solid line gives the linear fit to all data points ($R^2 = 0.82$, $P < 0.0001$). The dashed line shows ideal agreement between predicted and experimental $P_{\text{Open,S.S.}}$.

from 0.1 to 1 μM . Not all combinations included all 5 compounds. The data from 53 cells are shown in Fig. 6. A linear fit to all data points yielded an R^2 of 0.82 ($P < 0.0001$) with a regression slope of 0.99 ± 0.10 .

Discussion

Receptors consisting of $\alpha 4$, $\beta 2$ or $\beta 3$, and δ subunits are a major extrasynaptic type of GABA_A receptors in several brain regions such as the hippocampus and the thalamus^{26–29}. Prior studies have indicated that the $\alpha 4\beta\delta$ receptor has a high affinity to GABA, and is only moderately desensitized during prolonged application of agonist^{30–33}. Both properties support its presumed function to mediate tonic Cl^- conductance in response to ambient GABA, and the concentration profile of ambient GABA in the brain. The $\alpha 4\beta\delta$ receptor is also activated by taurine, endogenous potentiating steroids, and various GABAergic sedative and anesthetic agents^{3,14,20,30}. The overall goal of this study was to analyze the function of the $\alpha 4\beta 2\delta$ receptor in the presence of one or more activators and modulators under steady-state conditions.

Previous work has provided evidence for two types or isoforms of receptors resulting from the expression of $\alpha 4$, β ($\beta 2$ or $\beta 3$), and δ subunits. In electrophysiological recordings, this manifests as widely different sensitivities to the agonist. The high-affinity type has a GABA EC_{50} at < 100 nM whereas the low-affinity type has a GABA EC_{50} at > 1 μM . In some cases, concentration-response relationships show two components in a single cell indicating that both types of the receptor can express concurrently³¹. The underlying reason for differing sensitivity to the agonist is not fully established. Several studies have suggested that it is due to the “promiscuous” nature of the δ subunit that allows for variability in the assembly order of subunits and stoichiometry of the surface receptor. For example, Hartiadi *et al.*³⁴ showed that reduction in the ratio of $\alpha 4$ to $\beta 2$ cRNAs tends to generate receptors with high affinity to GABA whereas changes in δ have no effect. We previously showed that linking individual subunits to concatameric constructs enables selective generation of low- or high-affinity receptors³². In contrast, for receptors activated by the conformationally constrained analog of GABA, THIP, Meera *et al.*³⁵ proposed that the two types of behavior are simply due to a mixture of low-affinity $\alpha\beta$ and high-affinity $\alpha\beta\delta$ receptors, i.e., incomplete incorporation of δ in all surface receptors. We note that our study was conducted on the “high-affinity” isoform of the $\alpha 4\beta 2\delta$ receptor.

We have shown that the $\alpha 4\beta 2\delta$ receptor exhibits relatively high constitutive open probability ($P_{\text{Open,const}} = 0.1$). In the cyclic MWC model, high background activity is associated with enhanced sensitivity to agonist because of a lower energy barrier that needs to be crossed during transition from closed/resting to open/active^{9,36}. Despite the high $P_{\text{Open,const}}$, the receptor is only weakly activated by the endogenous agonists GABA and taurine. The maximal peak open probabilities were ~ 0.4 for either agonist. However, both GABA and taurine are relatively potent agonists, and the equilibrium dissociation constants for GABA (~ 15 nM) and taurine (10 μM) are near their reported extracellular concentrations of 5–30 nM and 10–25 μM , respectively^{37–39}. The receptor is weakly directly activated by the endogenous steroid $3\alpha 5\alpha\text{P}$ (maximal peak $P_{\text{Open}} \sim 0.2$), but the intravenous anesthetic propofol is a full agonist ($P_{\text{Open,max}} \sim 0.99$).

The estimate for Q ($=A/D$ in Fig. 1) was 0.52 in the presence of taurine, 0.78 in the presence of GABA, 0.89 with $3\alpha5\alpha P$, and 1.29 when the receptors were activated by propofol. Followup experiments showed that propofol similarly potentiates peak and steady-state currents from receptors activated by GABA. We infer that the observed difference in Q for GABA vs. propofol is a result of experimental imprecision rather than higher affinity of propofol to the open state as previously observed for the $\alpha1\beta2\gamma2L$ receptor²³. In subsequent simulations, we used a value of Q of 0.87, averaged from the individual estimates in the presence of taurine, GABA, $3\alpha5\alpha P$, or propofol.

We tested the independence of the actions of orthosteric and allosteric agents by coapplying various combinations of such agents, and comparing the observed $P_{Open,S.S.}$ with a predicted value calculated using Eq. (7), which assumes additive effects of each agonist and inhibitor. Overall there was a good agreement between predicted and observed data (Fig. 6). We infer that the actions GABA, taurine, propofol, $3\alpha5\alpha P$, and PS on the $\alpha4\beta2\delta$ receptor follow the basic rules of energetic additivity. We did not test energetic additivity of the drugs on peak responses.

The data indicate that taurine is a potent agonist of the $\alpha4\beta2\delta$ receptor with an EC_{50} (10 μM) near its extracellular concentration in the resting state in brain²⁷. This is in agreement with a previous study that showed increased tonic current and reduced action potential firing in the presence of 10–100 μM taurine in the thalamus²⁰. The reported EC_{50} for taurine on recombinant $\alpha4\beta2\delta$ receptors in HEK cells was, however, higher by several orders of magnitude²⁰. We propose that this discrepancy arises from the HEK cells preferentially expressing the low-affinity isoform of the $\alpha4\beta2\delta$ receptor³².

Taurine and GABA act additively rather than synergistically because both agonists interact with the same binding site. The calculated (Eq. (4)) steady-state P_{Open} of the $\alpha4\beta2\delta$ receptor is 0.24 in the presence of 30 nM GABA, 0.21 in the presence of 10 μM taurine, and 0.25 in the presence of GABA + taurine. The predicted $P_{Open,S.S.}$ in the simultaneous presence of physiological concentrations of major endogenous GABAergic agonists and modulators - 30 nM GABA³⁹, 10 μM taurine³⁷, 30 nM $3\alpha5\alpha P$ ⁴⁰, and 0.1 μM PS⁴⁰ - is 0.24. The addition of 1 μM propofol⁴¹ increases the $P_{Open,S.S.}$ to 0.28. Such a small potentiating effect may be expected given the low affinity of the receptor for propofol ($K_{propofol} > 50 \mu M$). The full extent of physiological significance of these predictions is unclear, but the results tend to argue against the $\alpha4\beta2\delta$ receptor being a significant target for propofol.

The overall predicted theoretical dynamic range of steady-state activity in the $\alpha4\beta2\delta$ receptor is relatively small, ranging from ~ 0.10 (constitutive activity) to ~ 0.45 (maximal allowable steady-state activity with $Q = 0.87$). We speculate that the $\alpha4\beta2\delta$ receptor acts to stabilize the membrane potential near the Cl^- reversal potential, and that surface receptor turnover plays a relatively large role in regulation of its function.

It is not fully established which affinity isoform is the best recombinant model of the native, neuronally-expressed extrasynaptic receptor. Several lines of evidence support the idea that the “high-affinity” isoform is a better analog of the native receptor. Submicromolar concentrations of THIP activate tonic current in cerebellar granule cells that is missing in the cells from δ knockout mice³⁵. The $\alpha4\beta3\delta$ receptors expressed in oocytes produced THIP concentration-response curves with a high-affinity component at < 100 nM (assumed to be analogous to high affinity to GABA) and a low-affinity component at $> 10 \mu M$ ³⁵. A low concentration (10–100 μM) of taurine elicits tonic inhibitory currents in thalamic neurons²⁰. This agrees with our study of the high-affinity isoform in oocytes where we saw strong activation in the 1–100 μM range (see above), but not with concentration-response studies of the $\alpha4\beta2\delta$ receptor expressed in HEK cells²⁰, which preferentially express the low-affinity isoform³². The physiological relevance of the high-affinity isoform is indirectly supported by the finding that the steroid alfaxalone elicits large currents in the presence of picrotoxin in hippocampal neurons transfected with $\alpha4\beta2\delta(T269Y)$ subunits³². Finally, we note that the high-affinity isoform of the $\alpha4\beta2\delta$ receptor with a GABA EC_{50} at 20 nM is expected to be responsive to extracellular (5–30 nM^{38,39}) GABA, unlike the low-affinity isoform with an $EC_{50} > 1 \mu M$.

Methods

Receptors and expression. The human $\alpha4\beta2\delta$ GABA_A receptors were expressed in *Xenopus laevis* oocytes. Harvesting of oocytes was conducted under the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. The animal protocol was approved by the Animal Studies Committee of Washington University in St. Louis (Approval No. 20170071).

The cDNAs of individual subunits in the pcDNA3 vector were linearized with Xba I (NEB Labs, Ipswich, MA). The cRNAs were generated using mMessage mMachine (Ambion, Austin, TX). The oocytes were injected with a total of 11 ng cRNA per oocyte in a 5:1:5 ($\alpha4:\beta2:\delta$) ratio. Following injection, the oocytes were incubated in bath solution (96 mM NaCl, 2 mM KCl, 1.8 mM $CaCl_2$, 1 mM $MgCl_2$, and 5 mM HEPES; pH 7.4) plus supplements (2.5 mM Na pyruvate, 100 U/ml penicillin, 100 $\mu g/ml$ streptomycin, and 50 $\mu g/ml$ gentamycin) at 15 °C for 3–4 days prior to conducting electrophysiological recordings.

Prior studies have indicated that the $\alpha4\beta\delta$ receptors in oocytes can assemble as isoforms characterized by high affinity to GABA (EC_{50} at tens to hundreds of nM) or low affinity (EC_{50} in the μM range) to GABA^{32–35}. The high-affinity isoform has been shown to be directly activated by the δ -specific drug DS-2 whereas the low-affinity isoform is potentiated but not directly activated by DS2^{34,42}. The underlying mechanism for this discrepancy is not fully understood, but distinct stoichiometries or subunit order in the two isoforms have been proposed as the cause^{32–34}. The isoform investigated in the present study had a high affinity to the transmitter and was directly activated by DS-2.

Electrophysiology and analysis of current responses. The recordings were conducted at room temperature using standard two-electrode voltage clamp. The pipets were filled with 3 M KCl. The oocytes were clamped at -60 mV. The chamber (RC-1Z, Warner Instruments, Hamden, CT) was perfused with bath solution (see above) at 5–8 ml/min. Solutions were gravity-applied from 30-ml glass syringes with glass luer slips via Teflon tubing, and switched manually.

The current responses were amplified with an Axoclamp 900A (Molecular Devices, Sunnyvale, CA) or OC-725C amplifier (Warner Instruments, Hamden, CT), digitized with a Digidata 1320 or 1200 series digitizer (Molecular Devices), and stored using pClamp (Molecular Devices).

A typical experiment entailed recording of baseline current for 10–20 s, followed by application of a test compound or a combination of compounds for 60–270 s (1–4.5 min), and by application of bath solution to demonstrate recovery. Due to long exposure times, not all cells yielded a full range of concentration–response data. Thus, the concentration–response relationships shown may reflect mean responses from cells exposed to an incomplete range of agonist concentrations. In such cases, the number of cell provided is given as a range of cell numbers for each concentration point. The effects of the inhibitory steroid PS were determined by coapplying the steroid with 0.3 μ M GABA. Each cell was tested with 1–3 concentrations of PS. Each cell was also tested with 10 μ M GABA + 50 μ M propofol to determine the maximal attainable peak response, which was assigned a P_{Open} of 1, and to which the responses to test drugs were compared. This approach assumes that peak responses are not affected by desensitization, i.e., that desensitization develops slowly compared to activation, and that the combination of GABA + propofol activates all resting receptors. The level of constitutive activity was determined by exposing the cells to 100–300 μ M picrotoxin.

The current traces were analyzed using Clampfit (Molecular Devices) to determine the amplitudes of peak and steady-state responses. If steady-state (defined as $\Delta I < 2\%$ during the last 20 s of agonist application) was not reached by the end of the agonist application, an estimate was made by exponential fitting of the current decay. Fitting was done using pClamp, to a single exponential or sums of up to three exponentials. The constant offset is reported as the steady-state response. The estimated value of the offset was relatively insensitive to the number of exponentials used in fitting (up to ~10% variability in the fitted offset).

Materials and chemicals. The salts and HEPES used to prepare the bath solution, GABA, and 3 α 5 α P were purchased from Sigma-Aldrich (St. Louis, MO). Propofol was purchased from MP Biomedicals (Solon, OH). Pregnenolone sulfate (PS) was bought from Tocris (Bio-Techne, Minneapolis, MN).

The stock solution of GABA was made in the bath solution at 500 mM, stored in aliquots at -20°C , and diluted on the day of experiment. Stock solution of propofol was made in DMSO at 200 mM and stored at room temperature. 3 α 5 α P was dissolved in DMSO at 10–20 mM and stored at room temperature. PS was dissolved in DMSO at 50 mM and stored at 4°C .

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 1 August 2019; Accepted: 18 October 2019;

Published online: 05 November 2019

References

1. Franks, N. P. Molecular targets underlying general anaesthesia. *Br J Pharmacol* **147**(Suppl 1), S72–81 (2006).
2. Weir, C. J., Mitchell, S. J. & Lambert, J. J. Role of GABA_A receptor subtypes in the behavioural effects of intravenous general anaesthetics. *Br J Anaesth* **119**, i167–i175 (2017).
3. Liao, Y., Liu, X., Jounaidi, Y., Forman, S. A. & Feng, H. J. Etomidate effects on desensitization and deactivation of $\alpha 4\beta 3\delta$ GABA_A receptors inducibly expressed in HEK293 TetR cells. *J Pharmacol Exp Ther* **368**, 100–105 (2019).
4. Tang, X., Hernandez, C. C. & Macdonald, R. L. Modulation of spontaneous and GABA-evoked tonic $\alpha 4\beta 3\delta$ and $\alpha 4\beta 3\gamma 2\text{L}$ GABA_A receptor currents by protein kinase A. *J Neurophysiol* **103**, 1007–1019 (2010).
5. Germann, A. L., Pierce, S. R., Burbidge, A. B., Steinbach, J. H. & Akk, G. Steady-state activation and modulation of the concatemeric $\alpha 1\beta 2\gamma 2\text{L}$ GABA_A Receptor. *Mol Pharmacol* **96**, 320–329 (2019).
6. Eaton, M. M. *et al.* Multiple non-equivalent interfaces mediate direct activation of GABA_A receptors by propofol. *Curr Neuropharmacol* **14**, 772–780 (2016).
7. Forman, S. A. & Stewart, D. Mutations in the GABA_A receptor that mimic the allosteric ligand etomidate. *Methods Mol Biol* **796**, 317–333 (2012).
8. Akk, G., Shin, D. J., Germann, A. L. & Steinbach, J. H. GABA type A receptor activation in the allosteric coagonist model framework: relationship between EC₅₀ and basal activity. *Mol Pharmacol* **93**, 90–100 (2018).
9. Forman, S. A. Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate. *Curr Opin Anaesthesiol* **25**, 411–418 (2012).
10. Amin, J. & Weiss, D. S. GABA_A receptor needs two homologous domains of the β -subunit for activation by GABA but not by pentobarbital. *Nature* **366**, 565–569 (1993).
11. Ruesch, D., Neumann, E., Wulf, H. & Forman, S. A. An allosteric coagonist model for propofol effects on $\alpha 1\beta 2\gamma 2\text{L}$ γ -aminobutyric acid type A receptors. *Anesthesiology* **116**, 47–55 (2012).
12. Shin, D. J., Germann, A. L., Steinbach, J. H. & Akk, G. The actions of drug combinations on the GABA_A receptor manifest as curvilinear isoboles of additivity. *Mol Pharmacol* **92**, 556–563 (2017).
13. Meera, P., Olsen, R. W., Otis, T. S. & Wallner, M. Etomidate, propofol and the neurosteroid THDOC increase the GABA efficacy of recombinant $\alpha 4\beta 3\delta$ and $\alpha 4\beta 3$ GABA_A receptors expressed in HEK cells. *Neuropharmacology* **56**, 155–160 (2009).
14. Akk, G., Bracamontes, J. & Steinbach, J. H. Activation of GABA_A receptors containing the $\alpha 4$ subunit by GABA and pentobarbital. *J Physiol* **556**, 387–399 (2004).
15. Storustovu, S. I. & Ebert, B. Pharmacological characterization of agonists at δ -containing GABA_A receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of $\gamma 2$. *J Pharmacol Exp Ther* **316**, 1351–1359 (2006).
16. Mortensen, M., Ebert, B., Wafford, K. & Smart, T. G. Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABA_A receptors. *J Physiol* **588**, 1251–1268.
17. Keramidas, A. & Harrison, N. L. Agonist-dependent single channel current and gating in $\alpha 4\beta 2\delta$ and $\alpha 1\beta 2\gamma 2\text{S}$ GABA_A receptors. *J Gen Physiol* **131**, 163–181 (2008).
18. Horikoshi, T., Asanuma, A., Yanagisawa, K., Anzai, K. & Goto, S. Taurine and β -alanine act on both GABA and glycine receptors in Xenopus oocyte injected with mouse brain messenger RNA. *Brain Res* **464**, 97–105 (1988).
19. Hadley, S. H. & Amin, J. Rat $\alpha 6\beta 2\delta$ GABA_A receptors exhibit two distinct and separable agonist affinities. *J Physiol* **581**, 1001–1018 (2007).
20. Jia, F. *et al.* Taurine is a potent activator of extrasynaptic GABA_A receptors in the thalamus. *J Neurosci* **28**, 106–115 (2008).
21. Kletke, O., Gisselmann, G., May, A., Hatt, H. & Sergeeva, O. A. Partial agonism of taurine at γ -containing native and recombinant GABA_A receptors. *PLoS One* **8**, e61733 (2013).
22. Ochoa-de la Paz, L. D. *et al.* Differential modulation of human GABAC- $\rho 1$ receptor by sulfur-containing compounds structurally related to taurine. *BMC Neurosci* **19**, 47 (2018).

23. Germann, A. L. *et al.* Steady-state activation and modulation of the synaptic-type $\alpha 1\beta 2\gamma 2L$ GABA_A receptor by combinations of physiological and clinical ligands. *Physiol Rep* **7**, e14230 (2019).
24. Akk, G., Bracamontes, J. & Steinbach, J. H. Pregnenolone sulfate block of GABA_A receptors: mechanism and involvement of a residue in the M2 region of the α subunit. *J Physiol* **532**, 673–684 (2001).
25. Eisenman, L. N., He, Y., Fields, C., Zorumski, C. F. & Mennerick, S. Activation-dependent properties of pregnenolone sulfate inhibition of GABA_A receptor-mediated current. *J Physiol* **550**, 679–691 (2003).
26. Chandra, D. *et al.* GABA_A receptor $\alpha 4$ subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. *Proc Natl Acad Sci USA* **103**, 15230–15235 (2006).
27. Porcello, D. M., Huntsman, M. M., Mihalek, R. M., Homanics, G. E. & Huguenard, J. R. Intact synaptic GABAergic inhibition and altered neurosteroid modulation of thalamic relay neurons in mice lacking δ subunit. *J Neurophysiol* **89**, 1378–1386 (2003).
28. Wisden, W., Laurie, D. J., Monyer, H. & Seeburg, P. H. The distribution of 13 GABA_A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. *J Neurosci* **12**, 1040–1062 (1992).
29. Stell, B. M., Brickley, S. G., Tang, C. Y., Farrant, M. & Mody, I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by δ subunit-containing GABA_A receptors. *Proc Natl Acad Sci USA* **100**, 14439–14444 (2003).
30. Brown, N., Kerby, J., Bonnett, T. P., Whiting, P. J. & Wafford, K. A. Pharmacological characterization of a novel cell line expressing human $\alpha 4\beta 3\delta$ GABA_A receptors. *Br J Pharmacol* **136**, 965–974 (2002).
31. Karim, N. *et al.* Low nanomolar GABA effects at extrasynaptic $\alpha 4\beta 1/\beta 3\delta$ GABA_A receptor subtypes indicate a different binding mode for GABA at these receptors. *Biochem Pharmacol* **84**, 549–557 (2012).
32. Eaton, M. M. *et al.* γ -aminobutyric acid type A $\alpha 4$, $\beta 2$, and δ subunits assemble to produce more than one functionally distinct receptor type. *Mol Pharmacol* **86**, 647–656 (2014).
33. Wongsamitkul, N., Baur, R. & Sigel, E. Toward understanding functional properties and subunit arrangement of $\alpha 4\beta 2\delta$ γ -aminobutyric acid, type A (GABA_A) Receptors. *J Biol Chem* **291**, 18474–18483 (2016).
34. Hartiadi, L. Y., Ahring, P. K., Chebib, M. & Absalom, N. L. High and low GABA sensitivity $\alpha 4\beta 2\delta$ GABA_A receptors are expressed in *Xenopus laevis* oocytes with divergent stoichiometries. *Biochem Pharmacol* **103**, 98–108 (2016).
35. Meera, P., Wallner, M. & Otis, T. S. Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA_A receptors. *J Neurophysiol* (2011).
36. Steinbach, J. H. & Akk, G. Applying the Monod-Wyman-Changeux allosteric activation model to pseudo-steady-state responses from GABA_A receptors. *Mol Pharmacol* **95**, 106–119 (2019).
37. Molchanova, S., Oja, S. S. & Saransaari, P. Characteristics of basal taurine release in the rat striatum measured by microdialysis. *Amino Acids* **27**, 261–268 (2004).
38. de Groote, L. & Linthorst, A. C. Exposure to novelty and forced swimming evoke stressor-dependent changes in extracellular GABA in the rat hippocampus. *Neuroscience* **148**, 794–805 (2007).
39. Zandy, S. L., Doherty, J. M., Wibisono, N. D. & Gonzales, R. A. High sensitivity HPLC method for analysis of *in vivo* extracellular GABA using optimized fluorescence parameters for *o*-phthalaldehyde (OPA)/sulfite derivatives. *J Chromatogr B Analyt Technol Biomed Life Sci* 1055–1056, (1–7 (2017).
40. Weill-Engerer, S. *et al.* Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. *J Clin Endocrinol Metab* **87**, 5138–5143 (2002).
41. Dawidowicz, A. L., Kalitynski, R. & Fijalkowska, A. Free and bound propofol concentrations in human cerebrospinal fluid. *Br J Clin Pharmacol* **56**, 545–550 (2003).
42. Wafford, K. A. *et al.* Novel compounds selectively enhance δ subunit containing GABA_A receptors and increase tonic currents in thalamus. *Neuropharmacology* **56**, 182–189 (2009).

Acknowledgements

Supported by the National Institutes of Health (grant GM108580), and funds from the Taylor Family Institute for Innovative Psychiatric Research. We thank Joe Henry Steinbach for many stimulating discussions.

Author contributions

S.R.P., T.C.S. and A.L.G. performed the experiments; S.R.P., T.C.S., A.L.G. and G.A. analyzed the data; A.L.G. and G.A. contributed to the study design; A.L.G. and G.A. prepared the figures and wrote the manuscript; all authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to G.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019